BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5196 related articles for article (PubMed ID: 3889169)

  • 1. Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma.
    Ernstoff MS; Duray P; Stenn K; Kirkwood JM
    J Invest Dermatol; 1985 May; 84(5):430-2. PubMed ID: 3889169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical study of HLA antigens and lymphocyte infiltration in melanocytic tumors.
    Kageshita T; Nagano H; Johno M; Ono T; Arao T; Imai K
    J Dermatol; 1986 Jun; 13(3):179-84. PubMed ID: 3537044
    [No Abstract]   [Full Text] [Related]  

  • 3. [Expression of HLA-Dr and CD1+ cells in malignant and benign pigmentary tumors].
    Ramírez-Bosca A; Valcuende-Cavero F; Rufat-Pérez MJ; Castells-Rodellas A
    Med Cutan Ibero Lat Am; 1989; 17(1):58-64. PubMed ID: 2474114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
    Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
    J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic dynamics of tumor progression in human malignant melanoma.
    Bröcker EB; Suter L; Brüggen J; Ruiter DJ; Macher E; Sorg C
    Int J Cancer; 1985 Jul; 36(1):29-35. PubMed ID: 3860479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Identification of protein S 100 and melanoma-associated antigens in a comparative study of malignant melanoma and nevus pathology].
    Monti M; Berti E; Cavicchini S; Paindelli MG; Terragni L
    G Ital Dermatol Venereol; 1985; 120(4):297-306. PubMed ID: 3899920
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies.
    Natali PG; Bigotti A; Nicotra MR; Nardi RM; Delovu A; Segatto O; Ferrone S
    Cancer Res; 1989 Mar; 49(5):1269-74. PubMed ID: 2917356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
    Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
    Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma.
    Natali P; Bigotti A; Cavaliere R; Liao SK; Taniguchi M; Matsui M; Ferrone S
    Cancer Res; 1985 Jun; 45(6):2883-9. PubMed ID: 3157450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.
    Kageshita T; Nakamura T; Yamada M; Kuriya N; Arao T; Ferrone S
    Cancer Res; 1991 Mar; 51(6):1726-32. PubMed ID: 1671829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Step-wise expression of melanoma-associated antigens in tumor progression].
    Lehmann JM; Holzmann B; Rothbächer U; Riethmüller G; Johnson JP
    Onkologie; 1989 Dec; 12(6):273-6. PubMed ID: 2696911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma.
    Carrel S; Schreyer M; Gross N; Zografos L
    Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852.
    von Stamm U; Bröcker EB; von Depka Prondzinski M; Ruiter DJ; Rümke P; Broding C; Carrel S; Lejeune FJ
    Melanoma Res; 1993 Jun; 3(3):173-80. PubMed ID: 8104570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
    Herlyn M; Guerry D; Koprowski H
    J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.
    Parmiani G; Fossati G; Taramelli D; Anichini A; Balsari A; Gambacorti-Passerini C; Sciorelli G; Cascinelli N
    Cancer Metastasis Rev; 1985; 4(1):7-26. PubMed ID: 3888384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
    White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
    J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigens associated with tumor progression in melanocytic neoplasia.
    Elder DE; Herlyn M
    Pigment Cell Res; 1992; Suppl 2():136-43. PubMed ID: 1409415
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.
    Holzmann B; Bröcker EB; Lehmann JM; Ruiter DJ; Sorg C; Riethmüller G; Johnson JP
    Int J Cancer; 1987 Apr; 39(4):466-71. PubMed ID: 3104215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 260.